Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of ExPEC9V vaccine for prevention of invasive extraintestinal pathogenic E. coli disease in older adults with prior urinary tract infection
MOH_2022-12-28_012257Phase 3Not yet recruiting
- Sponsor
- Janssen Vaccines & Prevention
- Start
- Dec 2022
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in extraintestinal pathogenic Escherichia coli infection comparing ExPEC9V with Placebo (2 arms). Primary endpoint: First episode of invasive extraintestinal pathogenic Escherichia coli disease. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
ExPEC9V
03
Conditions
extraintestinal pathogenic Escherichia coli infection
Beyond the preview
Go deeper on MOH_2022-12-28_012257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-12-28_012257.